After more than two years of negotiations, a number of states agreed to a $26 billion settlement with three large drug distributors and Johnson & Johnson for their roles in the opioids epidemic. Half a million deaths over two decades…
J&J said it's unlikely users would be harmed. The recall includes all can sizes and all levels of SPF, or sun protection factor. Consumers can contact the company for a refund.
By Linda A. Johnson, Associated Press
U.S. regulators on Monday added a new warning to Johnson & Johnson’s COVID-19 vaccine about links to a rare and potentially dangerous neurological reaction, but said it’s not entirely clear the shot caused the problem.
By Matthew Perrone, Mike Stobbe, Associated Press
The deal announced on Saturday requires Johnson & Johnson to make a series of payments over nine years that will cover the total. The drugmaker also agreed to end the manufacturing and distribution of opioids across New York and the…
By Associated Press
By Maureen Ferran, The Conversation
Various companies use different ingredients and different delivery systems in their COVID-19 vaccines. Researchers are investigating whether it's better for individuals to mix what's available.
In our news wrap Friday, the FDA will allow 10 million doses of the Johnson & Johnson vaccine from a troubled Baltimore factory to be used, but about 60 million doses will be thrown out. Also, the U.N. warned violence…
By Zeke Miller, Linda A. Johnson, Associated Press
The Food and Drug Administration announced that it had determined that two batches from the plant could be released. But it said several other batches are not suitable for use and additional batches are still under review.
By Matthew Perrone, Associated Press
The company said a FDA review concluded the shots remain safe and effective up to 4-1/2 months.
By Associated Press
The Supreme Court is leaving in place a $2 billion verdict in favor of women who claim they developed ovarian cancer from using Johnson & Johnson talc products.
Support Provided By: Learn more
Educate your inbox
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.